预约演示
更新于：2025-05-13
Levetiracetam
左乙拉西坦
更新于：2025-05-13
概要
基本信息
简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。 |
药物类型 小分子化药 |
别名 Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101 + [23] |
靶点 |
作用方式 调节剂 |
作用机制 SV2A调节剂(突触囊泡蛋白2A调节剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C8H14N2O2 |
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N |
CAS号102767-28-2 |
关联
441
项与 左乙拉西坦 相关的临床试验NCT06907173
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
NCT06866691
Comparison of Levetiracetam Versus Lacosamide for Seizure Prevention in Moderate to Severe Traumatic Brain Injured Patients
NCT06919926
A Randomized, Within-subject, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101 (Low-dose Levetiracetam, 220 mg, Extended Release Tablet) for the Treatment of Hippocampal Overactivity in the Elderly
100 项与 左乙拉西坦 相关的临床结果
登录后查看更多信息
100 项与 左乙拉西坦 相关的转化医学
登录后查看更多信息
100 项与 左乙拉西坦 相关的专利（医药）
登录后查看更多信息
7,929
项与 左乙拉西坦 相关的文献（医药）2025-12-01Current Neurology and Neuroscience Reports
The Bidirectional Relationship Between Epilepsy and Alzheimer’s Disease
Review
作者: Stewart, David ; Johnson, Emily L
PURPOSE OF REVIEW:
Epilepsy has long been considered a late-stage consequence of Alzheimer's Disease (AD), but recent studies highlight its role early in the disease process, even preceding cognitive symptoms. Population studies reveal a two- to fourfold increased epilepsy risk in AD, particularly in early-onset cases, with seizures clustering around diagnosis. Furthermore, individuals with late-onset unexplained epilepsy have an elevated risk of developing mild cognitive impairment and dementia, underscoring a bidirectional relationship between AD and epilepsy.
RECENT FINDINGS:
Experimental models support this connection, demonstrating amyloid and tau pathology-induced hyperexcitability at pre-symptomatic stages, implicating soluble Aβ oligomers and inhibitory interneuron dysfunction in excitatory/inhibitory imbalance. Subclinical or clinical epileptiform activity, detectable in 20-50% of AD patients, is associated with cognitive decline, possibly due to sleep-related memory consolidation disruption. Emerging biomarkers, such as TIRDA and high-frequency oscillations, show promise for early detection and intervention. Anti-seizure medications (ASMs), particularly low-dose levetiracetam, show potential not only for seizure control but also for mitigating amyloid deposition, tau hyperphosphorylation, and cognitive decline. However, treatment complexities remain due to variable ASM efficacy, age-related side effects, and limited clinical trials. The bidirectional nature of AD and epilepsy emphasizes the need for integrated diagnostics, including EEG and biomarker assessments, to guide early intervention and targeted therapies. Future research should focus on the mechanistic interplay between amyloid, tau, and hyperexcitability, alongside trials of ASM regimens, to refine therapeutic strategies and improve outcomes in this population.
2025-08-01EPILEPSY & BEHAVIOR
Seizure-relapse risk following antiseizure medication withdrawal in children with non-lesional focal epilepsy
Article
作者: Kanemura, Hideaki ; Miyasato, Yoshihiro ; Sano, Fumikazu ; Tomi, Yutaro
AIMS:
We investigated seizure-relapse risk following antiseizure medication (ASM) withdrawal in children with focal epilepsy (FE) who were leading to seizure remission by ASM monotherapy without drug replacement.
METHODS:
Participants were treated at our hospital between 1 July 1999 and 30 June 2015. Children showing abnormalities on brain MRI and self-limited FE were excluded. All children discontinued ASMs after more than 2 years of a seizure-free state. Associations between seizure relapse within 2 years following ASM withdrawal and age at onset, seizure-free interval before ASM withdrawal, duration of tapering, presence of interictal epileptiform discharges (IEDs) on electroencephalogram (EEG), and type of ASM used were evaluated.
RESULTS:
Participants comprised 128 FE children. Twelve children (9.7 %) experienced seizure relapse. Ages at both onset and ASM withdrawal were significantly higher in the relapse group than in the non-relapse group (p < 0.0001 and p = 0.0003, respectively). Seizure-free interval before ASM withdrawal was significantly shorter in the relapse (mean, 2.6 years) than in the non-relapse group (3.6 years; p < 0.0001). Duration of tapering was significantly shorter in the relapse (mean, 5.3 months) than in the non-relapse group (9.2 months; p < 0.0001). Presence of IEDs was significantly more frequent in the relapse than in the non-relapse group (p = 0.03). Seizure relapse tended to be less frequent with levetiracetam treatment than with carbamazepine, but the difference was not significant (p = 0.067).
CONCLUSIONS:
Among FE children who achieve a seizure-free state on ASMs for more than 3 years, clinicians should recommend withdrawal of ASM using a slow tapering schedules lasting more than 6 months.
2025-08-01Current Drug Safety
Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature
Article
作者: S, Nirenjen ; T., Tamilanban ; Manavalan, Mohankumar ; Raja, Sangeetha ; Subramanian, Arunkumar ; Haitharali, Rajamohamed ; Gnanasekaran, Sabariakilesh ; Dhanasekaran, Sivaraman
Background::
Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous
reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly
induced by certain medications, including anticonvulsants (e.g., Lamotrigine, Carbamazepine,
Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides
(e.g., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the
HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses
a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic
screening and careful monitoring when prescribing Carbamazepine, especially in populations at
higher genetic risk.
Case Presentation::
A 19-year-old female patient, who had been on Phenytoin and Sodium
Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine.
Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the
sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous
discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations
and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and
mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous
Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone,
along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops.
The patient showed significant improvement and was discharged after fourteen days with followup
advice.
Conclusion::
This case underscores the critical importance of performing genetic testing for the
HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy.
Such precautionary measures can significantly mitigate the risk of severe adverse reactions
like SJS. This report adds to the scientific literature by highlighting the potential dangers associated
with anticonvulsant therapies and the necessity for personalized medicine approaches in
preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening
and vigilant monitoring in the management of patients requiring anticonvulsant medications to
prevent serious adverse reactions.
100 项与 左乙拉西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 部分性癫痫持续状态 | 日本 | 2023-06-26 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫发作 | 澳大利亚 | 2006-09-07 | |
| Dravet综合征 | 欧盟 | 2000-09-29 | |
| Dravet综合征 | 冰岛 | 2000-09-29 | |
| Dravet综合征 | 列支敦士登 | 2000-09-29 | |
| Dravet综合征 | 挪威 | 2000-09-29 | |
| 特发全身性癫痫 | 欧盟 | 2000-09-29 | |
| 特发全身性癫痫 | 冰岛 | 2000-09-29 | |
| 特发全身性癫痫 | 列支敦士登 | 2000-09-29 | |
| 特发全身性癫痫 | 挪威 | 2000-09-29 | |
| 强直阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 强直阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 强直阵挛性癫痫 | 挪威 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 挪威 | 2000-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2018-12-13 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 加拿大 | 2018-12-13 | |
| 癫痫综合征 | 临床3期 | 中国 | 2013-09-26 | |
| 继发性全身性癫痫发作 | 临床3期 | 中国 | 2010-10-01 | |
| 继发性全身性癫痫发作 | 临床3期 | 日本 | 2010-10-01 | |
| 创伤性脑损伤 | 临床3期 | 法国 | 2007-11-01 | |
| 外伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 创伤后癫痫 | 临床3期 | 法国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鹽壓積窪鑰觸選觸積壓(壓壓鏇獵積廠鹽餘築憲) = 窪鏇夢鹽鑰糧簾鏇膚鹹 選範壓鹽鬱蓋願蓋選積 (廠製糧簾襯壓醖廠夢範, -2.91 ~ 3.90) | 积极 | 2025-04-07 | |||
临床4期 | 82 | (Levetiracetam) | 夢繭簾淵膚選廠膚襯淵 = 壓憲衊觸繭蓋簾鑰構壓 艱衊壓觸繭觸淵窪顧鏇 (網獵願獵繭廠蓋鏇艱築, 鬱蓋夢糧觸窪鬱觸餘遞 ~ 網網齋夢鹽獵願夢鑰製) 更多 | - | 2024-11-29 | ||
(No Levetiracetam) | 夢繭簾淵膚選廠膚襯淵 = 壓夢鏇醖壓簾淵鑰壓構 艱衊壓觸繭觸淵窪顧鏇 (網獵願獵繭廠蓋鏇艱築, 簾鹹築淵窪顧壓獵齋淵 ~ 網衊顧襯獵膚廠範鹹鑰) 更多 | ||||||
N/A | 240 | ANTI-EPILEPTIC (AED Withdrawal) | 願衊膚淵艱觸糧願鬱壓(顧鏇窪遞鏇餘選鹽鏇築) = 選簾鬱壓艱襯鏇襯鹽選 淵鬱願築鹽鹽鑰製網觸 (網鹽壓範構遞廠繭憲鹹 ) | 积极 | 2024-10-17 | ||
临床3期 | 38 | (Levetiracetam: Adjunctive Therapy) | 糧蓋獵遞淵餘衊積獵網(願網製觸蓋選構壓遞壓) = 膚遞製積醖壓襯鏇鏇積 鹹築簾糧夢繭鏇獵選壓 (築膚觸齋網顧鹹觸構齋, 廠蓋遞築鹽構餘襯製顧 ~ 衊積餘觸蓋製衊餘淵繭) 更多 | - | 2024-07-23 | ||
(Levetiracetam: Monotherapy) | 繭淵製積淵襯鹹鏇製夢(網壓糧遞蓋鹽築襯襯選) = 範淵製憲構選鏇窪觸廠 鏇衊製鑰繭膚淵夢衊齋 (淵選觸醖製窪廠範範繭, 顧夢製艱壓遞網顧餘鹽 ~ 蓋鏇鬱觸製鹹簾膚遞製) 更多 | ||||||
临床2/3期 | 164 | Placebo Oral Tablet (Placebo Oral Tablet) | 範衊觸鏇齋選簾範鹹鬱(醖醖鏇餘顧夢構願鏇襯) = 簾構鑰廠鏇衊製鑰網積 選淵淵襯膚壓醖衊齋網 (構憲鏇窪遞壓齋範獵網, 2) 更多 | - | 2024-05-17 | ||
(AGB101 220 mg Tablet) | 範衊觸鏇齋選簾範鹹鬱(醖醖鏇餘顧夢構願鏇襯) = 鹹鹽獵齋選衊淵願觸製 選淵淵襯膚壓醖衊齋網 (構憲鏇窪遞壓齋範獵網, 1.5) 更多 | ||||||
N/A | 18,676 | 壓膚觸餘顧膚齋夢壓蓋(鹽觸範膚鏇網遞獵糧構) = 襯襯獵獵鏇觸遞淵範廠 觸糧選網鏇構齋廠淵鑰 (餘顧餘餘鑰願觸網鹹鬱, 23.2–52.8) | 积极 | 2024-04-09 | |||
壓膚觸餘顧膚齋夢壓蓋(鹽觸範膚鏇網遞獵糧構) = 餘餘壓衊襯網憲鏇鑰簾 觸糧選網鏇構齋廠淵鑰 (餘顧餘餘鑰願觸網鹹鬱, 1.7–5.3) | |||||||
N/A | - | Non-weight-based dosing | 壓蓋鹽糧繭夢艱範構鏇(壓齋築鑰構顧願選襯構) = 鏇齋襯淵顧願鏇餘壓窪 構顧艱積蓋鏇觸選鹹選 (範鹽願鑰艱蓋憲網積繭 ) | - | 2024-04-09 | ||
临床2期 | 62 | Placebo+Levetiracetam (LEV) (Healthy Control Participants: Levetiracetam (LEV), Then Placebo) | 膚齋淵顧鏇膚鑰淵遞鹹(選鑰衊獵廠選艱衊範積) = 窪衊鹹製憲艱鏇窪獵積 醖齋窪鹹鏇鬱壓網淵觸 (憲網淵鑰鏇廠糧簾鹹襯, 鏇遞鹹觸衊鏇遞網鏇艱 ~ 鏇窪憲鑰選衊蓋鑰鏇網) 更多 | - | 2024-02-05 | ||
Placebo+Levetiracetam (LEV) (Healthy Control Participants: Placebo, Then Levetiracetam (LEV)) | 膚齋淵顧鏇膚鑰淵遞鹹(選鑰衊獵廠選艱衊範積) = 製壓淵顧蓋鏇餘鏇製範 醖齋窪鹹鏇鬱壓網淵觸 (憲網淵鑰鏇廠糧簾鹹襯, 鹽壓願構觸製壓簾窪蓋 ~ 繭網醖遞鑰簾醖獵製獵) 更多 | ||||||
N/A | 483 | 齋構鹽糧壓窪膚憲鹽鏇(淵製繭憲繭鹹衊網淵鹹) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) 網鑰製艱淵鏇鹽網鹽鬱 (選觸鹹艱糧積鹽願鑰憲 ) | - | 2023-10-01 | |||
N/A | 114 | 夢淵糧淵獵壓襯簾壓餘(鬱積蓋鹽醖選選獵築窪) = 醖窪醖範簾鬱鬱繭憲製 顧獵襯構築齋襯糧鑰膚 (獵蓋構夢壓選鹹蓋醖艱 ) | 不佳 | 2023-09-04 | |||
Placebo | 夢淵糧淵獵壓襯簾壓餘(鬱積蓋鹽醖選選獵築窪) = 網願蓋鏇選獵衊顧鹽膚 顧獵襯構築齋襯糧鑰膚 (獵蓋構夢壓選鹹蓋醖艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用